Eosinophilic Depletion with Benralizumab, Mepolizumab, and Depemokimab: A Modeling Study - PubMed
5 hours ago
- #Pharmacokinetic-Pharmacodynamic Modeling
- #Monoclonal Antibodies
- #Eosinophilic Asthma
- Study compared eosinophil depletion in severe asthma patients using benralizumab, mepolizumab, and depemokimab via pharmacokinetic/pharmacodynamic modeling.
- Benralizumab showed the highest blood eosinophil depletion: 99.5% at 12 weeks and 99.3% at 24 weeks, with sustained effects through 48 weeks.
- Mepolizumab and depemokizumab achieved lower depletion rates (around 76-82% at 12 and 24 weeks) compared to benralizumab.
- Models relied on digitized or predicted data, with results dependent on model quality and parameter estimates.
- Funding and conflicts: AstraZeneca-funded analysis; authors include AstraZeneca employees and contracted Pharmetheus staff.